What the Atopic March Is, and What the Data Actually Show
The 'atopic march' is the longitudinal observation that allergic diseases tend to appear in a predictable sequence during childhood: atopic dermatitis (eczema) in infancy, food allergy in late infancy through toddlerhood, allergic rhinitis (hay fever) in the preschool years, and asthma in school age. Cohort studies from multiple countries — including the German MAS, the UK Avon, and the US-based GAP and CHILD cohorts — confirm the pattern at population level. Approximately 30-50% of children with moderate-to-severe infant eczema will develop asthma by age 7; approximately 30% will develop a food allergy; approximately 50-70% will develop allergic rhinitis.
The mechanistic theory is the 'dual exposure hypothesis' advanced by Gideon Lack and colleagues: an immature skin barrier (the hallmark of infant eczema) allows environmental food proteins to cross into the skin's immune compartment, where they are encountered in a sensitizing rather than tolerogenic context — driving IgE-mediated allergic sensitization. Meanwhile, oral exposure to the same food proteins in the gut, where the immune system is primed for tolerance, does not drive sensitization but rather oral tolerance. The asymmetry — skin exposure sensitizes, oral exposure tolerizes — predicts that earlier oral introduction, in the window when the gut immune system is most plastic, should reduce allergy. This is exactly what the LEAP trial demonstrated.
The atopic march is not deterministic. Many infants with eczema do not develop later allergic disease; some children develop food allergy or asthma without prior eczema. But the eczema severity-allergy relationship is strong enough that the AAP and major allergy societies now consider moderate-to-severe infant eczema a meaningful risk factor that triggers proactive early allergen introduction guidance.
The LEAP Trial and the End of the Avoidance Era
Before 2015, US guidance recommended delaying introduction of peanut, egg, fish, and shellfish in high-risk infants until age 1, 2, or even 3 years. This advice — based on intuition and weak observational evidence — coincided with a doubling of peanut allergy prevalence in the US and UK between 1997 and 2010. The Learning Early About Peanut allergy (LEAP) randomized controlled trial, published in the New England Journal of Medicine in 2015, tested the inverse hypothesis: early introduction of peanut, between 4 and 11 months, in high-risk infants (severe eczema, egg allergy, or both).
The trial randomized 640 infants and followed them to age 5. The primary outcome — proportion of children with peanut allergy at age 5 — was 17.2% in the avoidance arm and 3.2% in the early-introduction arm. This is an 81% relative risk reduction and a 14 percentage-point absolute risk reduction. The follow-up LEAP-On trial confirmed that the benefit persisted even when early-introduction children stopped eating peanut at age 5 — suggesting that the early oral exposure had established durable oral tolerance.
The EAT (Enquiring About Tolerance) trial, published in 2016, extended the principle to multiple common allergens (peanut, egg, milk, sesame, fish, wheat) introduced from 3 months in exclusively breastfed infants. The per-protocol analysis showed significant reduction in food allergy in the early-introduction arm. The intention-to-treat analysis was less striking, largely because many families struggled to introduce the volumes of allergen specified by the protocol, but the directional signal supported the LEAP findings.
The 2017 NIAID Addendum Guidelines and the 2019 AAP/AAAAI consensus statement now recommend: introduce age-appropriate peanut-containing foods between 4 and 6 months in infants with severe eczema and/or egg allergy (after evaluation, sometimes with allergist-supervised first feeding); introduce around 6 months in infants with mild-moderate eczema; introduce 'freely' along with other complementary foods in infants without eczema or egg allergy. Egg introduction follows similar logic. The advice for delayed introduction of milk, soy, wheat, fish, shellfish, and tree nuts has also been withdrawn — there is no evidence for delaying any common allergen beyond 6 months.
Treating Infant Eczema: Emollients, Topical Steroids, and the Barrier Hypothesis
Atopic dermatitis (eczema) in infancy typically begins between 3 and 6 months with dry, itchy, red, scaly patches on the cheeks, scalp, and extensor surfaces of the arms and legs. The diaper area is typically spared (the barrier function is intact in the well-moisturized diaper zone). Atopic dermatitis affects approximately 15-20% of US infants, with peak prevalence at 3-12 months and gradual remission in many through childhood — approximately 60% are clear by age 7, though some persist into adulthood.
The first-line treatment is liberal emollient use — thick fragrance-free moisturizers (e.g., petrolatum-based ointments, ceramide-containing lotions) applied at least twice daily and after every bath. Bathing should be lukewarm, short (5-10 minutes), with mild fragrance-free cleansers used only where soap is needed, followed by patting (not rubbing) and immediate emollient application within 3 minutes ('soak and seal'). Hot water and bubble baths should be avoided. Cotton clothing, fragrance-free detergents, and avoidance of overheating reduce flare frequency.
For active inflammation (red, itchy, oozing patches), topical corticosteroids are first-line. Low-potency steroids (hydrocortisone 1% or 2.5%) are used on the face and intertriginous areas; mid-potency (triamcinolone 0.1%) on the body and extremities for short courses (5-14 days). Topical calcineurin inhibitors (tacrolimus, pimecrolimus) are second-line, useful for steroid-sensitive sites or as steroid-sparing maintenance. Topical PDE4 inhibitors (crisaborole) and JAK inhibitors are newer additions. The AAP and the American Academy of Dermatology emphasize that under-treatment of infant eczema — driven by parental fear of topical steroids — is the more common error than over-treatment, and that appropriate short-course use is safe and effective.
Several trials (e.g., BEEP, PreventADALL) tested the hypothesis that early aggressive emollient application from birth would prevent the development of eczema and downstream allergic disease in high-risk infants. The results have been mixed; early studies suggested benefit, but larger trials did not replicate the eczema-prevention effect, though the trials were not designed to detect food allergy prevention. The barrier hypothesis remains plausible but the prevention strategy of choice based on RCT evidence is early allergen introduction, not prophylactic emollients alone.
Asthma and Allergic Rhinitis: What Eczema Predicts and What Can Modify the Trajectory
Children with moderate-to-severe infant eczema have approximately 3-4 times the risk of developing asthma by age 7 compared to peers without eczema. The mechanism overlaps with the LEAP framework: early sensitization through impaired skin barrier extends to airborne allergens (dust mite, pet dander, pollens), which can drive both allergic rhinitis and allergic asthma. Children with the most severe and persistent eczema, those with food allergy, and those with a family history of atopic disease are at highest risk.
Modifiable factors that reduce asthma risk include exclusive or partial breastfeeding for the first 4-6 months (modest protective effect), avoidance of household tobacco smoke (substantial protective effect; secondhand smoke exposure approximately doubles asthma risk), reduction of indoor allergens in sensitized children (dust mite covers, removal of high-allergen pets in selected cases), influenza vaccination, RSV prevention with monoclonal antibody (nirsevimab) in eligible infants (which has been associated with reduced post-RSV wheeze episodes), and treatment of allergic rhinitis when it develops in early childhood. Specific allergen immunotherapy (sublingual or subcutaneous), started in pre-school or early school-age children with allergic rhinitis, has been shown to reduce progression to asthma.
What is no longer recommended: routine pet removal in non-sensitized infants (early dog or farm-animal exposure may actually be protective via microbial diversity effects); routine hypoallergenic infant formula in the absence of confirmed cow's milk protein allergy; routine probiotics for allergy prevention (the evidence is heterogeneous and the AAP does not endorse routine use, though some specific strains have weak supportive data); and prophylactic dietary restriction in pregnancy or lactation for the mother (no benefit).
Allergic rhinitis typically appears at age 3-7 and is treated with daily intranasal corticosteroids (the most effective single class), oral or intranasal antihistamines, and environmental allergen reduction. Identifying the dominant allergen via skin prick testing or serum specific IgE allows targeted intervention. The presence of allergic rhinitis is itself a risk factor for asthma development; aggressive treatment of rhinitis modestly reduces this risk.
The Practical Year-by-Year Plan for the Atopic-Risk Infant
Months 0-3: Establish good skin care from the start. Liberal fragrance-free emollient after baths, gentle cleansers, lukewarm water, cotton clothing, fragrance-free laundry detergent. Identify any developing eczema early and discuss with the pediatrician at well-child visits. Maintain a smoke-free environment.
Months 4-6: This is the LEAP/EAT window. For infants with severe eczema, egg allergy, or both: the AAP/NIAID guidance is to introduce peanut-containing foods (peanut puff, smooth peanut butter mixed into food — never whole peanuts due to aspiration risk) between 4 and 6 months, after evaluation by the pediatrician and consideration of allergist-supervised first feeding. For infants with mild-to-moderate eczema, introduce peanut around 6 months alongside other solids. For infants with no eczema or egg allergy, introduce common allergens (peanut, egg, dairy, wheat, soy, sesame, fish) freely with the introduction of solids. Continue twice-daily emollients and use topical steroids for active eczema flares without hesitation.
Months 6-12: Maintain regular ingestion of established allergens — once introduced, peanut and egg should be fed approximately 2-3 times per week to maintain oral tolerance. Stopping the food for several months after early introduction may be associated with re-sensitization in a subset. Continue eczema management; track flare patterns and triggers. Pediatrician follow-up at well-child visits. Allergist referral if any reaction occurs, if eczema is poorly controlled despite optimal topical therapy, or if there is concern for food allergy.
Years 1-3: Continue allergen-rich diet; eczema management can de-escalate as severity decreases for most children. Surveillance for allergic rhinitis symptoms (chronic nasal congestion, rubbing, watery eyes) and wheeze with viral illnesses. Tobacco smoke avoidance, attention to indoor air quality. Years 3+: Monitor for asthma symptoms (recurrent wheeze with colds, exercise intolerance, nighttime cough) and allergic rhinitis. Establish a pediatric primary care home and allergist relationship as needed. The atopic march is not destiny; with the right framework, the trajectory of the high-risk infant can often be bent toward better outcomes.